Author(s): K. Sai Girisha, Mohan Ram

Email(s): girisha.pharmd17@gmail.com

DOI: 10.5958/0974-360X.2017.00691.6   

Address: K. Sai Girisha*, Dr. Mohan Ram
Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University (VISTAS), Pallavaram,Chennai-600117, Tamilnadu, India.
*Corresponding Author

Published In:   Volume - 10,      Issue - 11,     Year - 2017


ABSTRACT:
Background: Chronic kidney disease (CKD) is a risk factor for end-stage renal failure and cardiovascular events. High incidence of anaemia is found in CKD stage 3 and 4. MIRCERA a continuous erythropoietin receptor activator is in development to provide anaemia correction and stable maintenance of haemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease (CKD). This study examined its efficacy when administered up to once monthly in patients with CKD. Methodology: This study involved a prospective examination of haemoglobin levels in CKD patients by collecting and documentation the information of the patient including patient demographics, past medical history, medication history, and laboratory data. All enrolled patients were assessed for haemoglobin levels for every 4 weeks. Results: The haemoglobin levels after 24 weeks treatment with Mircera were found to be significantly high when compared with baseline haemoglobin levels in CKD patients who didn’t receive Mircera (P<0.0001). Conclusion: Mircera demonstrated improved efficacy in treating anemia in patients with CKD when given twice weekly for 24 weeks.


Cite this article:
K. Sai Girisha, Mohan Ram. A Prospective Study on Efficacy of Mircera for Treating Anemia Associated with Chronic Kidney Disease. Research J. Pharm. and Tech 2017; 10(11): 3807-3809. doi: 10.5958/0974-360X.2017.00691.6


Recomonded Articles:

Author(s): Nimbalkar V.V., Pansare P.M., Nishane B.B.

DOI: 10.5958/0974-360X.2015.00310.8         Access: Open Access Read More

Author(s): Raj Kumar R, Praveen D, Palani Shanmugasundaram

DOI: 10.5958/0974-360X.2016.00164.5         Access: Open Access Read More

Author(s): M. Sumithra, Avantika Prabhabanik

DOI: 10.5958/0974-360X.2017.00036.1         Access: Open Access Read More

Author(s): Vaddi Mounika, S. Sarumathy, J. Anisha Ebens, T. S. Shanmugarajan

DOI: 10.5958/0974-360X.2017.00003.8         Access: Open Access Read More

Author(s): Vaseeha Banu T.S., Sandhya K.V., K.N. Jayaveera

DOI: Not Available         Access: Open Access Read More

Author(s): Barokar A.A., Wagh R.D., Baviskar D.T., Shaikh T.J.

DOI: Not Available         Access: Open Access Read More

Author(s): R. Suresh, D. Benitojohnson, C. Maheswari, R. Venkatnarayanan, R.Manavalan

DOI: 10.5958/0974-360X.2017.00128.7         Access: Open Access Read More

Author(s): Swathy. S, Gheena. S, Sri Varsha. L

DOI: 10.5958/0974-360X.2015.00291.7         Access: Open Access Read More

Author(s): Rao Rekha, Goswami Anju, Shekhar Shishant, Mahant Sheefali, Nanda Sanju

DOI: Not Available         Access: Open Access Read More

Author(s): V Rajesh Babu, Syeda Rana Nikhat, P Nivethithai, SH Areefulla

DOI: Not Available         Access: Open Access Read More

Author(s): Karthikeyan D, Vijayakumar S, Pandey V.P, Nandha Kumar J, Sengottuvelu S, T. Sivakumar T.

DOI:         Access: Open Access Read More

Author(s): Hitesh Jain, Rushi Panchal, Dilrose Pabla, Jaimini Patel, Mansi Khirwadkar

DOI: Not Available         Access: Open Access Read More

Author(s): Tapan Kumar Giri, Saumya Mishra, Dulal Krishna Tripathi

DOI: Not Available         Access: Open Access Read More

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags